Initiation (new start) criteria and criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:
Non-Formulary brodalumab (Siliq) will be covered on the prescription drug benefit for when the following criteria are met:

1. Prescriber is a dermatologist and patient has a diagnosis of psoriasis
   - Patient has tried and failed/intolerant to at least 2 of the following:
     - Adalimumab (criteria based)
     - Etanercept (criteria based)
     - Infliximab product
   - Patient has tried and failed/intolerant to or has contraindication to all of the following:
     - Secukinumab (criteria based)
     - Ustekinumab (criteria based)
     - Apremilast (criteria based)
     - Guselkumab (criteria based)
   - Patient does NOT have a diagnosis of Crohn’s disease
   - Prescriber has completed the Prescriber Certification for Siliq REMS